+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Aerosol administration of fenoterol hydrobromide (Th 1165a) in subjects with reversible obstructive airway disease



Aerosol administration of fenoterol hydrobromide (Th 1165a) in subjects with reversible obstructive airway disease



Chest 72(6): 731-736



Bronchodilatory and side effects of fenoterol hydrobromide (Th1165a; hydroxyphenylorciprenaline; Berotec) and isoproterenol given by inhalation were compared in a double-blind crossover study involving 20 volunteer subjects with reversible obstructive disease of the airways. Subjects inhaled medications from aerosol canisters containing fenoterol hydrobromide (0.1 mg, 0.2 mg, or 0.4 mg) or isoproterenol (0.15 mg) or an inert placebo propellant in a random sequence of five testing days. All active drugs substantially increased the forced expiratory volume in one second, the mean forced expiratory flow during the middle half of the forced vital capacity, and the specific conductance. The onset of bronchodilation after both fenoterol and isoproterenol was rapid, but the effect from fenoterol lasted much longer, up to eight hours. None of the medications cuased significant tachycardia or hypertension. After inhalation of 0.1 mg of fenoterol hydrobromide, none of the subjects reported nervousness, headache, tremor, or nausea, incontrast with results reported for isoproterenol, higher aerosol doses fo fenoterol, or oral administration of fenoterol. No additional therapeutic benefit was found in the administration of higher doses of fenoterol.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 039199137

Download citation: RISBibTeXText

PMID: 336306

DOI: 10.1378/chest.72.6.731


Related references

Fenoterol hydrobromide (Berotec, Th 1165a) 0.1% solution in the treatment of allergic rhinitis. Annals of Allergy 44(2): 112-115, 1980

Whole-body autoradiographic studies on the distribution and the placental transfer of fenoterol-hydrobromide (Th 1165a) in rats. Arzneimittel-Forschung 24(8): 1210-1213, 1974

Distribution and passage of tritium-labelled fenoterol hydrobromide (Th 1165a) in pregnant and lactating rabbits. Arzneimittel Forschung 24(8): 1213-1217, 1974

Studies on distribution and passage of tritium labelled fenoterol-hydrobromide (Th 1165a) in gravid and lactating rabbits. Arzneimittel-Forschung 24(8): 1213-1217, 1974

Acute effects of sublingual nifedipine on airway obstruction in patients with chronic obstructive pulmonary disease in comparison to fenoterol aerosol. Atemwegs- und Lungenkrankheiten 19(1): 41-44, 1993

Absorption, Distribution and Excretion of the Tritium-Labelled 2 Stimulator Fenoterol Hydrobromide Following Aerosol Administration and Instillation into the Bronchial Tree. Respiration 34(3): 131-140, 2009

Absorption, distribution and excretion of the tritium-labelled beta2 stimulator fenoterol hydrobromide following aerosol administration and instillation into the bronchial tree. Respiration 34(3): 131-140, 1977

Combined administration of ipratropium bromide (sch 1000) and fenoterol in patients with chronic obstructive airway disease. Wiener Klinische Wochenschrift 87(19): 653-656, 1975

Acute effects of albuterol aerosol in reversible obstructive airway disease. Annals of Allergy 47(5 Pt 2): 387-391, 1981

Two-month comparative study of tulobuterol aerosol versus fenoterol aerosol in patients with chronic obstructive lung disease. Lung 168 Suppl: 202-209, 1990

A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease. Drugs 64(15): 1671-1682, 2004

The effects of the fenoterol hydrobromide (Partusisten) aerosol on uterine activity and the cardiovascular system. British Journal of Obstetrics and Gynaecology 83(11): 864-869, 1976

Use of beta stimulating agents for aerosol in obstructive pulmonary emphysema long term effects from administration of terbutaline fenoterol salbutamol. Rassegna di Medicina Sperimentale 28(9): 582-586, 1981

Treatment of obstructive disease with fenoterol-ipratropiumbromid dosage aerosol (IK 6). Short and long-terms results. Medizinische Klinik 74(42): 1548-1552, 1979

Salmeterol and fenoterol-comparison of efficacy and safety in patients with reversible obstructive airways disease. European Respiratory Journal 7(Suppl. 18): 112S, 1994